# Arrowhead Pharmaceuticals share price today (Arrowhead Pharmaceuticals, Inc., ARWR)

> Arrowhead Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ARWR · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/arwr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $61.65 (+57.2% in a year)
- Revenue (Jun 2026): $75.3 M (+171.0% on a year ago)
- Profit (Jun 2026), incl. one-off: −$194 M (one-off item, see below)
- Operating margin: −226.0% (+370.2 points on a year ago)
- ROE: 0%, FY25
- ROIC: −101.1%, against a 10.9% cost of capital: −112.0 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Arrowhead Pharmaceuticals share price today? Arrowhead Pharmaceuticals, Inc.'s share price was $61.65 at the close on 4 November 2026. It has been moving sideways for 8 weeks. That is 14.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $39 and $88, and at that close it sat 46% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. Over the last 10 years the share price moved +976% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Arrowhead Pharmaceuticals pay? Arrowhead Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Arrowhead Pharmaceuticals on? Arrowhead Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Arrowhead Pharmaceuticals profitable? Arrowhead Pharmaceuticals, Inc. posted a net loss of $194 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $1.6 M. That loss is 258.2% of the quarter's revenue. The same quarter a year earlier lost $175 M. 9 of the last 12 reported quarters were loss-making. Read this profit with care: at −$194 M it is bigger than the quarter's whole revenue of $75.3 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −226.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Arrowhead Pharmaceuticals make, and is it growing? Arrowhead Pharmaceuticals, Inc. reported $75.3 M of revenue in the Jun 2026 quarter, +171.0% on the same quarter a year earlier. Over 4 years it has grown 56.5% a year on average. The last full year, FY25, came in at $829 M. The last four reported quarters add to $669 M. Recent pace: the last four quarters grew +3,515.3% on average, against 56.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.1%, against +66.8% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Arrowhead Pharmaceuticals keep? Arrowhead Pharmaceuticals, Inc.'s operating margin was −226.0% in the Jun 2026 quarter, 370.2 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −16,927.1% and 11.9%. The latest quarter is within that range. Across 5 years it has been between −16,927.1% and 11.9%, and FY25's 11.9% is the highest of them. Why the margin moved: operating margin changed +370.2 percentage points on the year while gross margin changed +0.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Arrowhead Pharmaceuticals' profit turning into cash? Arrowhead Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $180 M of operating cash against −$1.6 M of profit. After $22.7 M of spending on assets, $157 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Arrowhead Pharmaceuticals' cash go? Arrowhead Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $341 M on assets over the last 3 years. Averaged over those years that is 13.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $341 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Arrowhead Pharmaceuticals' P/E ratio, and how does it compare with its own history? Arrowhead Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Arrowhead Pharmaceuticals, Inc. at 10.5× its FY25 revenue of $829 M. The P/E comes back here once profit turns positive. ## Is the Arrowhead Pharmaceuticals business getting better or worse? Arrowhead Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 11 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Arrowhead Pharmaceuticals earn on its capital? Arrowhead Pharmaceuticals, Inc. earned a ROE of 0% in FY25. That is up from a low of −314% in FY24. Its return on capital used (ROIC) is 112.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −0.2% net margin and 0.60× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −0.2% net margin × 0.60× asset turnover × 2.75× leverage (assets divided by equity) ≈ −0.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −101.1% − 10.9% = −112.0 percentage points. The 10.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −101.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 16.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Arrowhead Pharmaceuticals have too much debt? Arrowhead Pharmaceuticals, Inc. has total debt of $1.4 B against shareholder equity of $466 M as of Jun 2026, so its debt is 2.96× its equity. Year by year, that ratio went from 0.06 in FY21 to 1.48 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Arrowhead Pharmaceuticals shareholding pattern? 8.9% of Arrowhead Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Arrowhead Pharmaceuticals from balance-sheet trouble? For Arrowhead Pharmaceuticals, Inc., the Z-score is 2.10. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.10 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Arrowhead Pharmaceuticals rank in its industry? There is no score against its industry: Arrowhead Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Arrowhead Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Arrowhead Pharmaceuticals in size? Arrowhead Pharmaceuticals is the 32nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Crinetics Pharmaceuticals, Inc., Cytokinetics, Incorporated and TG Therapeutics, Inc. Just below it: Corcept Therapeutics Incorporated, Praxis Precision Medicines, Inc. and ABIVAX Société Anonyme. ### Biotechnology companies close in size

1. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) $9 billion
2. [Cytokinetics, Incorporated](https://www.sectoralpha.in/us/stocks/cytk) $8.8 billion
3. [TG Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tgtx) $8.7 billion
4. Arrowhead Pharmaceuticals, Inc. $8.7 billion
5. [Corcept Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/cort) $8.7 billion
6. [Praxis Precision Medicines, Inc.](https://www.sectoralpha.in/us/stocks/prax) $8 billion
7. [ABIVAX Société Anonyme](https://www.sectoralpha.in/us/stocks/abvx) $7.8 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [CAE Inc.](https://www.sectoralpha.in/us/stocks/cae) $8.7 billion · Aerospace & Defense
2. [GitLab Inc.](https://www.sectoralpha.in/us/stocks/gtlb) $8.7 billion · Software - Infrastructure
3. Arrowhead Pharmaceuticals, Inc. $8.7 billion
4. [Victoria's Secret & Co.](https://www.sectoralpha.in/us/stocks/vsxy) $8.7 billion · Apparel Retail
5. [IDACORP, Inc.](https://www.sectoralpha.in/us/stocks/ida) $8.7 billion · Utilities - Regulated Electric

## What else do people ask about Arrowhead Pharmaceuticals? ### What were Arrowhead Pharmaceuticals's latest quarterly results? Arrowhead Pharmaceuticals, Inc. reported revenue of $75.3 M and a net loss of $194 M for the Jun 2026 quarter. Earnings per share were −$1.36. The operating margin was −226.0%, 370.2 percentage points higher than a year earlier (as of 4 November 2026). ### What is Arrowhead Pharmaceuticals's market cap? Arrowhead Pharmaceuticals, Inc.'s market capitalisation is $8.7 B at a stock price of $61.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Arrowhead Pharmaceuticals performing? Arrowhead Pharmaceuticals, Inc.'s share price has been moving sideways for 8 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Arrowhead Pharmaceuticals's stock price go up? This page does not forecast Arrowhead Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $61.65, and it has been moving sideways for 8 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Arrowhead Pharmaceuticals in its business cycle? Arrowhead Pharmaceuticals, Inc.'s FY25 operating margin was 11.9%, against a 5-year range of −16,927.1% to 11.9%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was −226.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Arrowhead Pharmaceuticals story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Arrowhead Pharmaceuticals a stock worth studying right now? What the numbers show: Arrowhead Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.